Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease

[1]  T. Sugiyama,et al.  Latent class analysis of 216 patients with adult-onset Still’s disease , 2022, Arthritis Research & Therapy.

[2]  K. Migita,et al.  Interferon-γ induces interleukin-6 production by neutrophils via the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway , 2021, BMC Research Notes.

[3]  P. Hur,et al.  Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. , 2021, Seminars in arthritis and rheumatism.

[4]  K. Nichols,et al.  Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome , 2021, Frontiers in Pharmacology.

[5]  P. Través,et al.  JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib , 2021, Annals of the Rheumatic Diseases.

[6]  K. Nichols,et al.  Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis , 2021, Frontiers in Immunology.

[7]  M. Dougados,et al.  Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study , 2020, Rheumatology.

[8]  M. Buch,et al.  Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease , 2020, RMD Open.

[9]  A. Risitano,et al.  Ruxolitinib for steroid-resistant acute GVHD. , 2020, Blood.

[10]  S. Ye,et al.  Macrophage activation syndrome associated with adult-onset Still’s disease: a multicenter retrospective analysis , 2020, Clinical Rheumatology.

[11]  Liyan Wan,et al.  Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China , 2020, Annals of the Rheumatic Diseases.

[12]  S. Ibrahim,et al.  Racial/Ethnic variations in morbidity and mortality in Adult Onset Still's Disease: An analysis of national dataset. , 2019, Seminars in arthritis and rheumatism.

[13]  Y. Pers,et al.  Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy. , 2019, Rheumatology.

[14]  T. Barnetche,et al.  Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy , 2019, Arthritis Research & Therapy.

[15]  O. Silvennoinen,et al.  Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases , 2019, BioDrugs.

[16]  E. Feist,et al.  Mechanisms, biomarkers and targets for adult-onset Still’s disease , 2018, Nature Reviews Rheumatology.

[17]  B. Fautrel,et al.  New Markers for Adult-Onset Still's Disease. , 2017, Joint, bone, spine : revue du rhumatisme.

[18]  Chengde Yang,et al.  A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease , 2017, Scientific Reports.

[19]  J. Dipersio,et al.  Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial , 2017, Journal of Hematology & Oncology.

[20]  A. Fischer,et al.  Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. , 2016, Blood.

[21]  M. González-Gay,et al.  Adult-onset Still's disease: Advances in the treatment. , 2016, Best practice & research. Clinical rheumatology.

[22]  T. Sumida,et al.  Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan , 2015, Modern rheumatology.

[23]  F. Martinon,et al.  Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart , 2014, Immunologic Research.

[24]  P. Sève,et al.  Adult-onset Still's disease. , 2014, Autoimmunity reviews.

[25]  T. Kishimoto,et al.  Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan , 2014, The Journal of Rheumatology.

[26]  H. Lévesque,et al.  Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. , 2013, Joint, bone, spine : revue du rhumatisme.

[27]  A. Mimori,et al.  Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome , 2011, Modern rheumatology.

[28]  J. Sibilia,et al.  Tocilizumab in refractory adult Still's disease , 2011, Arthritis care & research.

[29]  M. Schiller,et al.  Clinical Manifestations but not Cytokine Profiles Differentiate Adult-onset Still’s Disease and Sepsis , 2010, The Journal of Rheumatology.

[30]  E. Baldissera,et al.  Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. , 2010, Arthritis and rheumatism.

[31]  M. Inanç,et al.  Adult‐onset still's disease , 2009, International journal of clinical practice.

[32]  M. Kurrer,et al.  Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult‐onset Still's disease and concurrent macrophage activation syndrome , 2008, American journal of hematology/oncology.

[33]  G. Cook,et al.  Primer: inflammasomes and interleukin 1β in inflammatory disorders , 2008, Nature Clinical Practice Rheumatology.

[34]  C. Dinarello,et al.  Rapid responses to anakinra in patients with refractory adult-onset Still's disease. , 2005, Arthritis and rheumatism.

[35]  A. Tamakoshi,et al.  Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. , 1997, Journal of epidemiology.

[36]  G. Still,et al.  On a Form of Chronic Joint Disease in Children. , 1978, Medico-chirurgical transactions.